Results 101 to 110 of about 12,338 (219)
Unusual Cutaneous and Lymphatic Findings in an Adult Patient
JEADV Clinical Practice, EarlyView.
Sarah Preis +4 more
wiley +1 more source
, 2009 Jatin J Shah1, Robert Z Orlowski1,2, Sheeba K Thomas11Departments of Lymphoma/Myeloma; 2Experimental Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: The first in class proteasome ...
Sheeba K Thomas +2 more
core
Multiple myeloma is an incurable plasma cell malignancy. Most patients end up relapsing and developing resistance to antineoplastic drugs, like bortezomib. Antibiotic tigecycline has activity against myeloma.
Irene Gómez-Delgado +28 more
core +1 more source
Haematologica, 2015 We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone ...
Maximilian Merz +22 more
doaj +1 more source
Neoplasia: An International Journal for Oncology Research, 2010 The proteasome inhibitor bortezomib is clinically approved for the treatment of multiple myeloma. However, long-term remissions are difficult to achieve, and myeloma cells often develop secondary resistance to proteasome inhibitors.
Silke Meister +6 more
doaj +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, EarlyView.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Bortezomib attenuates murine collagen-induced arthritis
, 2009 OBJECTIVES: Nuclear factor kappa B (NF-kappaB) is a major regulator of pivotal proinflammatory cytokines in the pathogenesis of rheumatoid arthritis (RA).
이수곤, 이상원, 박용범
core +1 more source
Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries
British Journal of Pharmacology, EarlyView.Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley +1 more source
British Journal of Pharmacology, EarlyView.This study compares the molecular mechanisms of chemotherapy‐related peripheral neurotoxicity of two proteasome inhibitors, bortezomib and carfilzomib, using a multidisciplinary approach to reveal that, alongside shared effects on mitochondria structure and function, the more neurotoxic drug BTZ has specific effects on microtubules and mitochondrial ...
Federico Iseppon +27 more
wiley +1 more source